1. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma;Choueiri;N Engl J Med,2023
2. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial;Powles;Lancet,2022
3. Ljungberg B, Albiges L, Bedke J, et al. EAU guidelines on renal cell carcinoma. Arnhem, The Netherlands: European Association of Urology; 2023. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Renal-Cell-Carcinoma-2023.pdf.
4. Top ten lessons learned from trials in oligometastatic cancers;Tan;Cancer Res Treat,2023